Tuesday, 19 Jun 2018

You are here

FDA Approves Tremfya (guselkumab) for Plaque Psoriasis

The U.S. Food and Drug Administration (FDA) has approved the IL-23 inhibitor, Tremfya (guselkumab), for patients with moderate to severe plaque psoriasis.

The drug received an expedited regulatory review following application of an FDA Priority Review Voucher.

After loading doses at weeks 0 and 4, guselkumab is given as 100 mg subcutaneously (prefilled syringe) every eight weeks. In clinical studies, patients receiving Tremfya experienced significant improvement in skin clearance and greater improvement in symptoms of plaque psoriasis including itch, pain, stinging, burning and skin tightness when compared with placebo at week 16.

The clinical development program included more than 2,000 patients in the Phase 3 VOYAGE 1, VOYAGE 2 and NAVIGATE studies, which have been previously presented or published in peer-reviewed journals. In a head-to-head trial, guselkumab beat adalimumab (ADA) with PASI90 results of 73% compted to 2.9% on placebo and 50% percent on ADA.

The NAVIGATE study tested the effectiveness of Tremfya in patients who had an inadequate response to ustekinumab and found 28-31% of Tremfya-treated patients were considered cleared or almost cleared versus 14% of UST treated patients at 12 weeks.

There are no contraindications or boxed warnings. Most common (≥1%) adverse reactions associated with Tremfya include upper respiratory infections, headache, injection site reactions, arthralgia,diarrhea, gastroenteritis, tinea infections, and herpes simplex infections. Elevated hepatic enzymeswere reported more frequently in the Tremfya group (2.6%) than in the placebo patients (1.9%). 

Guselkumab has been shown to be ineffective in rheumatoid arthritis, and is currently under study in psoriatic arthritis and ankylosing spondylitis. 

The addition of Tremfya will crowd a growing market for psoriatic therapies and will compete with existing approve therapies including the TNF inhibitiors, the IL-17 inhibitors (secukinumab, ixekizumab) and apremilast. Next month, the FDA will convene a hearing over the application to approve tofacitinib for psoriatic arthritis.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Increased Risk of Infection in Psoriasis and Psoriatic Arthritis

As we gather more knowledge about psoriatic arthritis ( PsA) and psoriasis (PSO) over time, and achieve better outcomes with new therapies, more questions arise about quality of life, survival  and comorbidities in PsA and PSO. Similarly to RA, we learned about increased risk of CVD and malignancy. With more data compiled in cohorts it is possible now to ask the same questions as we asked in RA.

Cardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA

Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides. A single center cross -sectional observational study was designed to conduct deeper analysis of Cardiovascular Risk Factors (CVRF) in patients with PsA, PSO without arthritis and SpA without PSO (THU 0297).

MRI Imaging for Sacroiliitis Requires Bone Marrow Edema for Reliability

de Winter and colleagues from the Netherlands have reported on magnetic resonance imaging of the sacroiliac joints of healthy subjects, patients with axial spondyloarthritis, runners and those with chronic back pain, and found a high incidence of sacroiliitis in many, but that deep bone marrow edema was most specific for those with axial SpA.

Cancer Risk Raised in Psoriatic Arthritis

Patients with psoriatic arthritis (PsA) were at increased risks for malignancy, and possibly more so if they were treated with conventional disease-modifying antirheumatic drugs (DMARDs), a meta-analysis found.

In nine cohort studies that included more than 43,000 PsA patients, the pooled relative risk for overall malignancy was 1.29 (95% CI 1.04-1.60) compared with the general population, according to Yunyun Fei, MD, and colleagues from Peking Union Medical College in Beijing.

Trends in Psoriatic Arthritis Treatment 2004-2015

Lee and colleagues from Brigham and Women's Hospital have analyzed the last decade of disease‐modifying antirheumatic drugs (DMARDs) use in patients with psoriatic arthritis (PsA) and found nearly 40% were treated with a bDMARD, along with a decreasing trend in complete DMARD discontinuations.